Wuhan General Group (China), Inc.

OTC: WUHN · Healthcare · Medical - Pharmaceuticals

PublicHQ Cape Town, NVReports USD

#1108 of 1,394 Healthcare companies by revenuebottom-quartile growth

EA Score

——

FH —DQ —GM —SS 58

v0.1 · 5/100 weight · pillars only

↑ workforce scale, balance-sheet leverage · ↓ operating margin, net margin

Methodology →

Revenue TTM

$14.2k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$1.7M

Employees

700

Market cap

$16.5k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$14.2k$14.2k2021

Net income-$1.7M-$1.7M2021

Operating income-$1.7M-$1.7M2021

Total assets$763.7k$763.7k2021

Liabilities$186.4k$186.4k2021

Equity$577.4k$577.4k2021

Revenue trend

FY2019 – FY2021 · USD

FY19

$33.3k

FY20

$14.2k

FY21

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Wuhan General Group (China), Inc. booked $14.2k in FY2021 revenue, contracting 57% year over year — slower than 84% of Healthcare companies we track, at a -12086.9% net margin.

Peers · Healthcare

Lattice Biologics Ltd.——ARYx Therapeutics, Inc.——Itoco Inc.——AREV Life Sciences Global Corp——

Key facts

CEOJeff Robinson

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersCape Town, NV

ExchangeOTC: WUHN

Employees700

IPO date2006-04-19

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.